Numerai GP LLC Decreases Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Numerai GP LLC decreased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 54.7% during the fourth quarter, Holdings Channel.com reports. The fund owned 3,042 shares of the life sciences company’s stock after selling 3,676 shares during the period. Numerai GP LLC’s holdings in Illumina were worth $407,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of ILMN. Capital World Investors boosted its stake in Illumina by 408.6% in the 4th quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company’s stock worth $2,408,721,000 after purchasing an additional 14,481,232 shares in the last quarter. Brown Advisory Inc. lifted its stake in shares of Illumina by 54,220.9% during the fourth quarter. Brown Advisory Inc. now owns 1,912,639 shares of the life sciences company’s stock worth $255,586,000 after buying an additional 1,909,118 shares during the period. Norges Bank purchased a new stake in shares of Illumina during the fourth quarter valued at $228,714,000. Bessemer Group Inc. grew its holdings in shares of Illumina by 32,837.5% during the fourth quarter. Bessemer Group Inc. now owns 1,348,131 shares of the life sciences company’s stock valued at $180,152,000 after buying an additional 1,344,038 shares during the last quarter. Finally, WCM Investment Management LLC increased its position in shares of Illumina by 26.6% in the 4th quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock valued at $551,625,000 after acquiring an additional 867,673 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Stephens reaffirmed an “overweight” rating and set a $156.00 price target on shares of Illumina in a research report on Tuesday, March 11th. Robert W. Baird decreased their target price on Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a report on Wednesday, March 5th. Piper Sandler dropped their target price on Illumina from $190.00 to $185.00 and set an “overweight” rating on the stock in a research report on Thursday. Morgan Stanley reduced their price target on shares of Illumina from $136.00 to $100.00 and set an “equal weight” rating for the company in a research report on Monday. Finally, Citigroup dropped their price objective on shares of Illumina from $90.00 to $85.00 and set a “neutral” rating on the stock in a report on Monday, April 7th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $130.70.

Insider Activity

In related news, CFO Ankur Dhingra purchased 6,100 shares of the firm’s stock in a transaction that occurred on Monday, May 12th. The shares were purchased at an average cost of $81.21 per share, with a total value of $495,381.00. Following the purchase, the chief financial officer now owns 24,906 shares of the company’s stock, valued at $2,022,616.26. This represents a 32.44% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.17% of the company’s stock.

Illumina Trading Up 3.4%

ILMN stock opened at $80.90 on Friday. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $156.66. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The firm has a market cap of $12.80 billion, a P/E ratio of -10.53, a PEG ratio of 1.60 and a beta of 1.35. The company’s 50-day simple moving average is $78.50 and its 200-day simple moving average is $111.80.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.96 by $0.01. The company had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.03 billion. Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Illumina’s revenue for the quarter was down 1.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.98 earnings per share. As a group, equities analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.